BioCrossroads Celebrates 2nd Anniversary of Growing Central Indiana Life Sciences Sector; 2nd Year Report Details Progress of Regional Biotech Effort.Business Editors/Health/Medical Writers INDIANAPOLIS--(BUSINESS WIRE)--Feb. 19, 2004 It's a great time to live and work at the BioCrossroads, according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. prominent Central Indiana corporate leaders, elected officials and academics. Central Indiana's BioCrossroads initiative celebrates its second anniversary in mid-February with significant progress towards making the region a global life sciences hub. BioCrossroads, which began as the Central Indiana Life Sciences Initiative in February 2002, is a coalition of the Central Indiana Corporate Partnership, Eli Lilly Eli Lilly can refer to:
 `, -d`), main campus at West Lafayette, Ind. . The initiative has expanded to include the active
participation of regional partners like Roche Diagnostics Roche Diagnostics Division is a subsidiary of Hoffmann-La Roche which manufactures equipment and reagents for research and medical diagnostic applications. Internally, it is organized into six major business areas: Roche Applied Science, Roche Centralized Diagnostics, Roche , Dow
AgroSciences Dow AgroSciences LLC is a wholly owned subsidiary of the Dow Chemical Company specializing in not only agricultural chemicals such as pesticides, but also seeds and biotechnology solutions. The company is based in Indianapolis, Indiana, in the United States. , Guidant, the Cook Group, Rose-Hulman Institute of
Technology Rose-Hulman Institute of Technology (abbreviated RHIT), formerly Rose Polytechnic Institute, is a small, private, non-sectarian college specializing in teaching engineering, mathematics, and science. RHIT is highly regarded for its undergraduate engineering program. and others.
In 2003, the initiative changed its name to BioCrossroads and began a focus on entrepreneurial development within eight industry target areas: agribiotech, biosensors, cancer treatment, cardiovascular, evidence-based medicine evidence-based medicine Decision-making 'The use of scientific data to confirm that proposed diagnostic or therapeutic procedures are appropriate in light of their high probability of producing the best and most favorable outcome'. See Meta-analysis. , neuroscience neu·ro·sci·ence n. Any of the sciences, such as neuroanatomy and neurobiology, that deal with the nervous system. neuroscience the embryology, anatomy, physiology, biochemistry and pharmacology of the nervous system. , proteomics, and sports-centered life sciences. Two additional areas, bioimaging and biomarkers, have been added as opportunities after an analysis of commercialization opportunities in the original eight target areas. Leveraging the corporate and academic research assets already existing in the region within these areas, BioCrossroads leaders are concentrating on growing the next generation of life sciences businesses. "We have a sound growth strategy and are putting the tools in place to execute it," said Chuck Schalliol, a senior Eli Lilly executive recruited to serve as BioCrossroads' CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "With Central Indiana's mix of corporate and academic resources, I can't think of a better place to start and grow a company or form commercial partnerships." An annual report released by BioCrossroads details the progress made in its second year, including: -- New organizational structure  This article has no lead section.To comply with Wikipedia's lead section guidelines, one should be written. with a Chairman and Board of Directors (Dr. Gus Watanabe) and a President and Chief Executive Officer (Chuck Schalliol). -- A new identity - BioCrossroads - and marketing campaign to reach the "bio-entrepreneur," as well as making investments in entrepreneurial resources like the Indiana Venture Center. -- Studies of each industry target area undertaken by teams of industry and academic experts, yielding significant commercialization opportunities. The Indiana Centers for Applied Protein Sciences, a Bioimaging Center, Biomarkers discovery effort and an evidence-based medicine initiative are projects that are currently being pursued. Opportunities in the other target areas, like biosensors, cardiovascular and agribiotech are being evaluated. -- The formation of Indiana Future Fund I, a $73 million "fund of funds" that will invest in a national network of venture capital funds that will, in turn, focus on Indiana opportunities. -- Completion of a workforce gap analysis that targets critical human capital needs. The City of Indianapolis is also funding life sciences training grants through the Indianapolis Private Industry Council. "During its second year, BioCrossroads has made great strides: exploring the sciences areas where Central Indiana can be competitive, investing in entrepreneurial support services support services Psychology Non-health care-related ancillary services–eg, transportation, financial aid, support groups, homemaker services, respite services, and other services and tapping into new venture capital resources," finished Schalliol. "Central Indiana is a hot spot in the bio-economy, and more great things lie ahead." About BioCrossroads BioCrossroads is Central Indiana's life science network, a public-private collaboration that supports the region's research and corporate strengths while encouraging new business development. Central Indiana is a global life sciences hub, with 900 private companies employing a skilled workforce of over 85,000, working with multiple nationally-recognized research institutions. With government, industry and academic resources aligned to accelerate business growth, the region is fertile ground for investors and entrepreneurs to build new ventures. Learn more at www.biocrossroads.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion